ALAMEDA, Calif.--(BUSINESS WIRE)--Celera Corporation (NASDAQ:CRA) and its collaborators at The University of Texas, Baylor College of Medicine, and Brigham and Women’s Hospital, today reported that, among non-users of aspirin, those who carry an LPA gene variant were at increased risk of coronary heart disease (CHD), compared with noncarriers. Carriers of the LPA variant were not at increased risk among those who use aspirin. This study was conducted among the middle aged Caucasian men and women of the ARIC study. These results were presented today at the 2009 Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference under the auspices of the American Heart Association in Washington, DC.
